Capricor Therapeutics price target raised to $25 from $24 at Ladenburg

Ladenburg analyst Aydin Huseynov raised the firm’s price target on Capricor Therapeutics to $25 from $24 and keeps a Buy rating on the shares. Capricor seems to have advanced in its regulatory negotiations with the FDA, meaning a possible rolling BLA submission may start as early as Q4, the analyst tells investors. Meanwhile, Capricor disclosed, for the first time, that the company will be entitled to 30%-50% of gross revenues from CAP-1002 sales in DMD, which is “significantly higher than what we assumed before,” the analyst added.